GlassScriptPhysician profile
Supha K Arthurs
NPI 1790765865
$5,484.29
in general payments reported to CMS, 2019-2025
44 companies · $477 in 2025
The $477 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $975 · 2020: $187 · 2021: $158 · 2022: $932 · 2023: $1,542 · 2024: $1,213 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,231.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,188.24 | 2019-2025 | Avycaz, Mavyret, Dalvance |
| Melinta Therapeutics, LLC | $704.75 | 2019-2025 | Rezzayo, Orbactiv, Kimyrsa |
| Gilead Sciences, INC. | $406.72 | 2019-2023 | |
| Harmony Biosciences LLC | $311.42 | 2023-2025 | Wakix |
| Astrazeneca Pharmaceuticals LP | $304.63 | 2019-2024 | Airsupra, Tezspire, Breztri |
| Merck Sharp & Dohme LLC | $274.47 | 2019-2025 | Dificid, Zerbaxa, Pifeltro |
| Viiv Healthcare Company | $239.28 | 2019-2020 | |
| Pfizer INC. | $197.29 | 2022-2024 | |
| Glaxosmithkline, LLC. | $157.75 | 2022-2025 | Nucala, Shingrix |
| Janssen Biotech, INC. | $132.21 | 2020-2025 | Tremfya, Stelara, Simponi Aria |
| Grifols USA, LLC | $116.38 | 2022-2024 | Prolastin-C Liquid, Xembify, Gamunex-C |
| Insmed, INC. | $113.08 | 2022-2024 | Arikayce |
| Ferring Pharmaceuticals INC. | $99.20 | 2023 | Rebyota |
| Baxter Healthcare | $89.95 | 2023-2025 | Hillrom - Vest System Model 105 Home Care |
| Allergan, INC. | $89.17 | 2019-2020 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Supha Arthurs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.